Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

757 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas.
Manconi L, Coviello E, Canale F, Giannoni L, Minetto P, Guolo F, Clavio M, Marcolin R, Cea M, Cagnetta A, Gobbi M, Miglino M, Ballerini F, Lemoli RM. Manconi L, et al. Among authors: gobbi m. Leuk Lymphoma. 2020 Jan;61(1):84-90. doi: 10.1080/10428194.2019.1658102. Epub 2019 Sep 4. Leuk Lymphoma. 2020. PMID: 31480933
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
De Astis E, Clavio M, Raiola AM, Ghiso A, Guolo F, Minetto P, Galaverna F, Miglino M, Di Grazia C, Ballerini F, Marani C, Pastori G, Mitscheunig L, Cruciani F, Lovera D, Varaldo R, Ghiggi C, Lemoli RM, Bacigalupo A, Gobbi M. De Astis E, et al. Among authors: gobbi m. Ann Hematol. 2014 Dec;93(12):2011-8. doi: 10.1007/s00277-014-2143-8. Epub 2014 Jul 4. Ann Hematol. 2014. PMID: 24989345
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.
Guolo F, Minetto P, Clavio M, Miglino M, Di Grazia C, Ballerini F, Pastori G, Guardo D, Colombo N, Kunkl A, Fugazza G, Rebesco B, Sessarego M, Lemoli RM, Bacigalupo A, Gobbi M. Guolo F, et al. Among authors: gobbi m. Am J Hematol. 2016 Aug;91(8):755-62. doi: 10.1002/ajh.24391. Epub 2016 Jun 15. Am J Hematol. 2016. PMID: 27084986 Free article.
Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives.
Guolo F, Minetto P, Clavio M, Miglino M, Lemoli RM, Gobbi M. Guolo F, et al. Among authors: gobbi m. Biosci Trends. 2017 Mar 22;11(1):110-114. doi: 10.5582/bst.2016.01221. Epub 2017 Jan 24. Biosci Trends. 2017. PMID: 28123146 Free article.
Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients.
Guolo F, Minetto P, Clavio M, Marcolin R, Miglino M, Passannante M, Caviglia F, Ballerini F, Tedone E, Kunkl A, Mangerini R, Contini P, Colombo N, Cagnetta A, Cea M, Carminati E, Pugliese G, Gobbi M, Lemoli RM. Guolo F, et al. Among authors: gobbi m. Leuk Lymphoma. 2020 Jul;61(7):1695-1701. doi: 10.1080/10428194.2020.1737685. Epub 2020 Mar 18. Leuk Lymphoma. 2020. PMID: 32186422
WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia.
Miglino M, Colombo N, Pica G, Grasso R, Clavio M, Bergamaschi M, Ballerini F, Ghiso A, Ghiggi C, Mitscheunig L, Beltrami G, Cagnetta A, Vignolo L, Lucchetti MV, Aquino S, Pierri I, Sessarego M, Carella AM, Gobbi M. Miglino M, et al. Among authors: gobbi m. Leuk Lymphoma. 2011 Oct;52(10):1961-9. doi: 10.3109/10428194.2011.585673. Leuk Lymphoma. 2011. PMID: 21942328
Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression.
Miglino M, Colombo N, Grasso R, Marani C, Clavio M, Pica GM, Ballerini F, Ghiggi C, Minetto P, Guolo F, Carella AM, Gobbi M. Miglino M, et al. Among authors: gobbi m. Leuk Lymphoma. 2012 Nov;53(11):2214-7. doi: 10.3109/10428194.2012.681658. Epub 2012 May 21. Leuk Lymphoma. 2012. PMID: 22475129
De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question".
Clavio M, Cruciani F, Minetto P, Guolo F, Ballerini F, Marani C, De Astis E, Aquino S, Bergamaschi M, Mitscheunig L, Grasso R, Colombo N, Ghiggi C, Lovera D, Pastori G, Avenoso D, Miglino M, Gobbi M. Clavio M, et al. Among authors: gobbi m. Ann Hematol. 2013 Oct;92(10):1309-18. doi: 10.1007/s00277-013-1780-7. Epub 2013 May 18. Ann Hematol. 2013. PMID: 23686116
757 results